Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)

View Full Paper
Ask AI
Bookmark
Share

Authors

AJAlexandria JensenAPAndrew J. PortugueseNANadine Abdallah

Discussion

Loading...

Member takes

Overview

Real-world data show CAR-T therapy achieves similar outcomes in older patients, suggesting efficacy without increased toxicity.

Key Points

  • This research evaluates the safety and efficacy of BCMA CAR-T therapy in patients aged 75 and older with relapsed or refractory multiple myeloma.
  • Retrospective analysis of RRMM patients receiving BCMA CAR-T at 15 centers.
  • Patients aged 75+ were 2:1 propensity-matched to younger patients based on various factors.
  • Continuous outcomes were analyzed using multivariable linear regression; binary outcomes with logistic regression; and time-to-event endpoints with Cox proportional-hazards models.
  • 194 older patients (≥75 years) and 388 younger patients (<75 years) were analyzed.
  • Median PFS was 28.7 months for cilta-cel and 16.4 months for ide-cel in older patients.
  • Safety profiles, including CRS and ICANS, were comparable across age groups.

Cite This Study

Jensen et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e14bhttps://doi.org/10.1182/blood-2025-6375
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CAR-T in the older adults: Real-world survival and toxicity in patients ≥ 75 years with relapsed/refractory multiple myeloma.2026
  2. 2Comparative outcomes of CAR-T therapy in elderly (≥70 Years) versus younger (&amp;lt;70 Years) patients with relapsed/refractory multiple myeloma: A real-world propensity-matched cohort study2025
  3. 3Impact of age on outcomes of CAR-T cell therapy in multiple myeloma, DLBCL, and follicular lymphoma: A real-world multi-center propensity-matched analysis2025
  4. 4Age-related differences in clinical outcomes among hospitalized recipients of CAR-T cell therapy: A national readmission database analysis2025
  5. 5Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study2024 · 35 citations